Phase II study of mifepristone (RU486) in refractory ovarian cancer.
Gynecol Oncol. 2000 Jun;77(3):429-32.
CONCLUSION: Mifepristone has activity against ovarian cancer resistant to cisplatin and paclitaxel. The drug is well tolerated. Further studies need to be performed when this drug becomes more widely available in the United States.
Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types.
Anticancer Res. 2010 Feb;30(2):623-8.
CONCLUSION: Our data demonstrate a palliative role for the use of mifepristone in cancer therapy. Progesterone receptor antagonists should be given a therapeutic trial in larger controlled studies of various malignancies in humans.
Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon – case report.
Anticancer Res. 2009 May;29(5):1611-3.
RESULTS: Both patients not only survived far longer than expected but had marked improvement in their quality of life similar to mice. Though the metastatic lesions did not disappear, no new ones appeared for a long time and the ones present did not grow. The drug was extremely well tolerated. CONCLUSION: The use of progesterone receptor antagonists may present a novel immunotherapy to help fight cancer. A larger controlled study is needed.